The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01809574

Enrollment

Registered

2013-03-12

Start date

2013-05-31

Completion date

2016-03-31

Last updated

2015-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective Tissue Disease, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Keywords

Interstitial lung disease, Idiopathic pulmonary fibrosis, Connective tissue disease

Brief summary

We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age above 18 years old * ILD according to ATS/ERS guidelines * Signed inform consent

Exclusion criteria

* Previous lung surgery * Other significant systemic disease

Design outcomes

Primary

Measure	Time frame
The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists.	two years

Countries

Israel

Contacts

Primary ContactDavid Shitrit, Dr.

davids3@clalit.org.il097471556

Outcome results